18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
The purpose of the study is to conduct research of a new PET radiopharmaceutical in cancer patients. The uptake of the novel radiopharmaceutical 18F-FPPRGD2 will be assessed in study participants with glioblastoma multiforme (GBM), gynecological cancers, and renal cell carcinoma (RCC) who are receiving antiangiogenesis treatment.
Checked against the public recordLast updated Oct 3, 2019 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Diagnostic
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Sponsor
- Sanjiv Sam Gambhir
- Interventions being studied
- Drug: 18F-fludeoxyglucose (18F-FDG); Drug: 18F-FPPRGD2
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Provides written informed consent * Diagnosed with advanced NSCLC, breast cancer, GBM or other cancers (such as head and neck, colorectal, pancreatic, renal cancers); patients will undergo anti-angiogenesis treatment or treatment with other drugs that may alter angiogenesis * Able to remain still for duration of each imaging procedure (about one hour) Exclusion Criteria: * Pregnant or nursing * Contraindication to MRI * History of renal insufficiency (only for MRI contrast administration)
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Stanford University, School of MedicineStanford, California
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 3, 2019. Always confirm current availability with the study team.